Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors

NCT03212274 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03212274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03212274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 30, 2019
Completion date
July 31, 2027
Enrollment
89 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, glioblastoma, recurrent cholangiocarcinoma, recurrent glioma, recurrent malignant solid neoplasm, who grade 2 glioma, who grade 3 glioma